Domvanalimab (DOM)

DRUG2 trials

Sponsors

Gilead Sciences, MedSIR

Conditions

Advanced or Metastatic Non-Small-Cell Lung CancerLung CancerPDL-1 PositiveResectable Non-Small-Cell Lung CancerTriple Negative Breast Cancer

Phase 2

Study of Novel Treatment Combinations in Patients With Lung Cancer

Active, not recruitingNCT05633667

Gilead SciencesAdvanced or Metastatic Non-Small-Cell Lung Cancer, Lung Cancer, Resectable Non-Small-Cell Lung Cancer

Start: 2023-03-16End: 2029-09-01Updated: 2026-06-01

Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC

WithdrawnNCT07134556

MedSIRPDL-1 Positive, Triple Negative Breast Cancer

Start: 2026-04-01End: 2028-12-28Updated: 2026-05-01

Related Papers

Abstract A008: TIGIT, CD155 (PVR), and Trop-2 expression characterization across histology and PD-L1 subgroups in non−small cell lung cancer (NSCLC)

Molecular Cancer Therapeutics2025-10-22

VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom)+zimberelimab (zim)+chemotherapy (chemo) or zim+chemo followed by adjuvant dom+zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2024-06-012 citations

VELOCITY-Lung: A phase (Ph) 2 study evaluating safety and efficacy of domvanalimab (dom) + zimberelimab (zim) + sacituzumab govitecan (SG), or etrumadenant (etruma) + dom + zim, or etruma + zim in patients (pts) with treatment-naïve metastatic non-small cell lung cancer (mNSCLC).

Journal of Clinical Oncology2023-06-012 citations

Abstract CT049: VELOCITY-Lung: A phase 2 study evaluating safety and efficacy of sacituzumab govitecan (SG) + zimberelimab (zim) + etrumadenant (etruma) in patients (pts) with advanced or metastatic non-small cell lung cancer (mNSCLC) progressing on or after platinum (PT)-based chemotherapy and checkpoint inhibitors (CPI)

Cancer Research2023-04-14